deltatrials
Terminated PHASE2 NCT00142168

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Phase II Study of CC-5103 and Rituximab in Waldenstrom's Macroglobulinemia

Sponsor: Beth Israel Deaconess Medical Center

Conditions Waldenstrom's Macroglobulinemia
Interventions CC-5103 (lenalidomide) Rituximab
Updated 9 times since 2017 Last updated: Mar 23, 2016 Started: Sep 30, 2004 Primary completion: May 31, 2006 Completion: Apr 30, 2008

A PHASE2 clinical study on Waldenstrom's Macroglobulinemia, this trial is terminated or withdrawn. The trial is conducted by Beth Israel Deaconess Medical Center and has accumulated 9 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 4 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • Celgene Corporation
  • Dana-Farber Cancer Institute
  • Genentech, Inc.
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States